Computer‐assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences

The immunology of human papillomavirus (HPV) infections has peculiar characteristics. The long latency for cervical cancer development after primary viral infection suggests mechanisms that may aid the virus in avoiding the host immunosurveillance and establishing persistent infections. In order to understand whether molecular mimicry phenomena might explain the ability of HPV to avoid a protective immune response by the host cell, sequence similarity between HPV16 E7 oncoprotein and human self‐proteins was examined by computer‐assisted analysis. Data were obtained showing that the HPV16 E7 protein has high and widespread similarity to several human proteins involved in a number of critical regulatory processes. In addition, multiple identical and different E7 peptide motifs are present in the same human protein. Thus, sharing of common motifs between viral oncoproteins and molecules of normal cells may be one cause underlying the scarce immunogenicity of HPV infections. The hypothesis is advanced that synthetic peptides harbouring viral motifs not and/or scarcely represented in the host's cellular proteins may represent a valuable immunotherapeutic approach for cervical cancer treatment.

[1]  V. Schirrmacher,et al.  Modification of tumor cells by a low dose of Newcastle Disease Virus. , 1988, European journal of immunology.

[2]  H. Moch,et al.  Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. , 1998, Anticancer research.

[3]  R. Lerner,et al.  Antibodies that react with predetermined sites on proteins. , 1983, Science.

[4]  I. Auger,et al.  Molecular mimicry reflected through database screening: serendipity or survival strategy? , 1996, Immunology today.

[5]  Alphonse García,et al.  Protein phosphatase 2A is a critical regulator of protein kinase C ζ signaling targeted by SV40 small t to promote cell growth and NF‐κB activation , 1997 .

[6]  S. Suhai,et al.  Human papillomavirus type 16 DNA sequence. , 1985, Virology.

[7]  G. Tortolero-Luna,et al.  Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. , 1995, Viral immunology.

[8]  Terri K. Attwood,et al.  The PRINTS protein fingerprint database in its fifth year , 1998, Nucleic Acids Res..

[9]  S. Papa,et al.  Cell Growth and Oncogenesis , 1998, Molecular and Cell Biology Updates.

[10]  M Peakman,et al.  Molecular mimicry in the MHC: hidden clues to autoimmunity? , 1996, Immunology today.

[11]  H. zur Hausen,et al.  Papillomavirus infections--a major cause of human cancers. , 1996, Biochimica et biophysica acta.

[12]  Hans-Werner Mewes,et al.  The PIR-International Protein Sequence Database , 1992, Nucleic Acids Res..

[13]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[14]  A. Garcia,et al.  Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation. , 1997, The EMBO journal.

[15]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  I. Frazer,et al.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. McMillan,et al.  The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2Ld molecule: implications for vaccine design and immunotherapy. , 1997, Molecular immunology.

[18]  C. Lacey,et al.  Toward a human papillomavirus vaccine. , 1998, Dermatologic clinics.

[19]  M. Tommasino,et al.  E7 protein of human papillomaviruses and its interaction with cellular pathways , 1998 .

[20]  M. Feltkamp,et al.  Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. , 1994, Molecular immunology.

[21]  H. Fleury,et al.  [Serological study of the virus responsible for hemorrhagic fever in an urban population of Cameroon]. , 1988, Bulletin de la Societe de pathologie exotique et de ses filiales.

[22]  Cathy H. Wu,et al.  The PIR-International Protein Sequence Database , 1999, Nucleic Acids Res..

[23]  I. Frazer,et al.  Immunology of papillomavirus infection. , 1996, Current opinion in immunology.

[24]  Rolf Apweiler,et al.  The SWISS-PROT protein sequence data bank and its new supplement TREMBL , 1996, Nucleic Acids Res..

[25]  D. Pardoll,et al.  Antigen‐specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein , 1998, International journal of cancer.

[26]  M. Oldstone Molecular mimicry and immune‐mediated diseases , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  P. Bonnier,et al.  c-myc protein and Ki-67 antigen immunodetection in patients with uterine cervix neoplasia: correlation of microcytophotometric analysis and histological data. , 1993, Gynecologic oncology.

[28]  M. von Knebel Doeberitz,et al.  Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions , 1994, Journal of virology.

[29]  R. Rossen,et al.  Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. , 1986, Cancer research.

[30]  R. Wood,et al.  Identical defects in DNA repair in xeroderma pigmentosum group G and rodent ERCC group 5 , 1993, Nature.

[31]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.